Nivolumab (Opdivo®) for muscle invasive urothelial carcinoma. HTA ID: 22046

Assessment Status Full HTA submission received from Applicant
HTA ID 22046
Drug Nivolumab
Brand Opdivo®
Indication Is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC.
Assessment Process
Rapid review commissioned 01/07/2022
Rapid review completed 08/08/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab for this indication compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 31/08/2022
Pre-submission consultation with Applicant 29/11/2022
Full submission received from Applicant 21/02/2023